The Effect of Empagliflozin Treatment on Epicardial Adipose Tissue and Cardiac Function in Patients With Type 2 Diabetes Mellitus - PubMed
5 hours ago
- #Empagliflozin
- #Type 2 Diabetes
- #Epicardial Adipose Tissue
- Empagliflozin treatment (10 mg daily for 6 months) in patients with type 2 diabetes without cardiovascular disease led to a significant reduction in epicardial adipose tissue (EAT) thickness.
- Significant improvements were observed in metabolic parameters (fasting glucose, HbA1c, LDL-C, HDL-C) and inflammatory markers (CRP, neutrophil-to-lymphocyte ratio).
- Diastolic function indices (E/e', isovolumic relaxation time, deceleration time) improved, while left ventricular ejection fraction remained stable.
- Changes in EAT thickness did not correlate with changes in HbA1c, BMI, CRP, or diastolic parameters, but showed a moderate inverse correlation with baseline EAT.
- Due to the single-arm study design without a control group, findings are hypothesis-generating and require confirmation in controlled studies to establish causality and mechanisms.